Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215163 · ClinicalTrials.gov registry record · Phase 2
Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00215163 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 17 participants.
The verdict
NCT00215163, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Both pharmacotherapeutic and psychosocial interventions have domenstrated efficacy for PTSD. However, although these interventions can be helpful, many patients remain symptomatic despite initial treatment. In this study, we will examine the relative efficacy of the addition of paroxetine-CR compared to placebo for patients remaining symptomatic despite a brief and intensive course of cognitive-behavioral therapy (CBT).
Interventions
- DRUG Cognitive-behavioral therapy and paroxetine-CR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2002-12 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00215163
The ClinicalTrials.gov registry entry for NCT00215163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cognitive-behavioral therapy and paroxetine-CR is the first listed.
NCT00215163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00215163 about?
NCT00215163 is a clinical study titled "Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy". Both pharmacotherapeutic and psychosocial interventions have domenstrated efficacy for PTSD. However, although these interventions can be helpful, many patients remain symptomatic despite initial treatment. In this study, we will examine the relative efficacy of the addition of paroxetine-CR compare...
What is the current status of trial NCT00215163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2002-12. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00215163?
The interventions under investigation include: Cognitive-behavioral therapy and paroxetine-CR (DRUG).
Who is sponsoring clinical trial NCT00215163?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.